Maher, Toby M.

Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort

Organ, L. A., Duggan, A.-M. R., Oballa, E., Taggart, S. C., Simpson, J. K., Kang’ombe, A. R., Braybrooke, R., Molyneaux, P. L., North, B., Karkera, Y., et al. (2019) · Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 139

Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype

Inoue, Y., Kaner, R. J., Guiot, J., Maher, T. M., Tomassetti, S., Moiseev, S., Kuwana, M., & Brown, K. K. (2020) · Chest

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 133

Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis

John, A. E., Graves, R. H., Pun, K. T., Vitulli, G., Forty, E. J., Mercer, P. F., Morrell, J. L., Barrett, J. W., Rogers, R. F., Hafeji, M., et al. (2020) · Nature Communications

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisCell Adhesion Molecules Research

Cited by 131

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study

Cottin, V., Koschel, D., Günther, A., Albera, C., Azuma, A., Sköld, C. M., Tomassetti, S., Hormel, P., Stauffer, J. L., Strombom, I., et al. (2018) · ERJ Open Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPharmacovigilance and Adverse Drug Reactions

Cited by 121

Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries

Maher, T. M., Molina-Molina, M., Russell, A.-M., Bonella, F., Jouneau, S., Ripamonti, E., Axmann, J., & Vancheri, C. (2017) · BMC Pulmonary Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 108

Home monitoring in interstitial lung diseases

Wijsenbeek, M. S., Moor, C. C., Johannson, K. A., Jackson, P. D., Khor, Y. H., Kondoh, Y., Rajan, S. K., Tabaj, G. C., Varela, B. E., van der Wal, P., et al. (2023) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 98

Biomarker signatures for progressive idiopathic pulmonary fibrosis

Clynick, B., Corte, T. J., Jo, H. E., Stewart, I., Glaspole, I. N., Grainge, C., Maher, T. M., Navaratnam, V., Hubbard, R., Hopkins, P. M. A., et al. (2022) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 86

Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis

Kolb, M., Crestani, B., & Maher, T. M. (2023) · European Respiratory Review

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPhosphodiesterase function and regulation

Cited by 85

Evidence for a Functional Thymic Stromal Lymphopoietin Signaling Axis in Fibrotic Lung Disease

Datta, A., Alexander, R., Sulikowski, M. G., Nicholson, A. G., Maher, T. M., Scotton, C. J., & Chambers, R. C. (2013) · The Journal of Immunology

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisIL-33, ST2, and ILC Pathways

Cited by 73

Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.

Corte, T. J., Behr, J., Cottin, V., Glassberg, M. K., Kreuter, M., Martinez, F. J., Ogura, T., Suda, T., Wijsenbeek, M., Berkowitz, E., et al. (2025) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 70

Identifying barriers to idiopathic pulmonary fibrosis treatment: a survey of patient and physician views

Maher, T. M., Swigris, J. J., Kreuter, M., Wijsenbeek, M., Cassidy, N., Ireland, L., Axmann, J., & Nathan, S. D. (2018) · Respiration

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 69

Metformin does not affect clinically relevant outcomes in patients with idiopathic pulmonary fibrosis

Spagnolo, P., Kreuter, M., Maher, T. M., Wuyts, W., Bonella, F., Corte, T. J., Kopf, S., Weycker, D., Kirchgaessler, K.-U., & Ryerson, C. J. (2018) · Respiration

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 61

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

Corte, T. J., Lancaster, L., Swigris, J. J., Maher, T. M., Goldin, J. G., Palmer, S. M., Suda, T., Ogura, T., Minnich, A., Zhan, X., et al. (2021) · BMJ Open Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 59

The role of precision medicine in interstitial lung disease

Maher, T. M., Nambiar, A. M., & Wells, A. U. (2022) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 38

No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone

Richeldi, L., Fletcher, S., Adamali, H., Chaudhuri, N., Wiebe, S., Wind, S., Hohl, K., Baker, A., Schlenker-Herceg, R., Stowasser, S., et al. (2019) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPharmacogenetics and Drug Metabolism

Cited by 34

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)

Maher, T. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A.-M., Kreuter, M., Oldham, J. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., et al. (2023) · BMJ Open Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 28

Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis

Maher, T. M., Schlecker, C., Luedtke, D., Bossert, S., Zoz, D. F., & Schultz, A. (2022) · ERJ Open Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPhosphodiesterase function and regulation

Cited by 26

Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial

Maher, T. M., Jenkins, R. G., Cottin, V., Nishioka, Y., Noth, I., Selman, M., Song, J. W., Ittrich, C., Diefenbach, C., Stowasser, S., et al. (2024) · ERJ Open Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 7

Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis

Jenkins, R. G., Cottin, V., Nishioka, Y., Noth, I., White, E. S., Ittrich, C., Diefenbach, C., Rohr, K. B., Selman, M., & Maher, T. M. (2024) · ERJ Open Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 6